Drug Search Results
More Filters [+]

PPV-06

Alternative Names: ppv-06, ppv06, ppv 06
Latest Update: 2024-05-31
Latest Update Note: Clinical Trial Update

Product Description

PPV-06 immunotherapy targets interleukin-6 (IL-6), a key molecule of the immune system whose overproduction is involved in many inflammatory and autoimmune diseases.

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Peptinov
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PPV-06

Countries in Clinic: France

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Osteoarthritis, Knee

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PPV06-01

P1

Completed

Osteoarthritis, Knee

2023-02-28

21%

Recent News Events

Date

Type

Title